Cargando…
New Insights into the Use of Empagliflozin—A Comprehensive Review
Empagliflozin is a relatively new drug that, as an inhibitor of the sodium–glucose cotransporter 2 (SGLT2), causes increased urinary glucose excretion and thus contributes to improved glycemic control, better glucose metabolism, reduced glucotoxicity and insulin resistance. Although its original use...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775057/ https://www.ncbi.nlm.nih.gov/pubmed/36552050 http://dx.doi.org/10.3390/biomedicines10123294 |
_version_ | 1784855550381522944 |
---|---|
author | Forycka, Joanna Hajdys, Joanna Krzemińska, Julia Wilczopolski, Piotr Wronka, Magdalena Młynarska, Ewelina Rysz, Jacek Franczyk, Beata |
author_facet | Forycka, Joanna Hajdys, Joanna Krzemińska, Julia Wilczopolski, Piotr Wronka, Magdalena Młynarska, Ewelina Rysz, Jacek Franczyk, Beata |
author_sort | Forycka, Joanna |
collection | PubMed |
description | Empagliflozin is a relatively new drug that, as an inhibitor of the sodium–glucose cotransporter 2 (SGLT2), causes increased urinary glucose excretion and thus contributes to improved glycemic control, better glucose metabolism, reduced glucotoxicity and insulin resistance. Although its original use was to induce a hypoglycemic effect in patients with type 2 diabetes mellitus (T2DM), empagliflozin has also shown a number of other beneficial effects by demonstrating a nephroprotective effect, and it has proven to be a breakthrough in the treatment of heart failure (HF). Empagliflozin has been shown to reduce hospitalizations for HF and the number of deaths from cardiovascular causes. Empagliflozin treatment also reduces the incidence of renal events, including death from renal causes, as well as the risk of end-stage renal failure. Empagliflozin appears to be a fairly well-tolerated and safe drug. In patients with inadequate glycemic control, empagliflozin used in monotherapy or as an adjunct to therapy effectively lowers fasting blood glucose, postprandial blood glucose, average daily glucose levels, glycated hemoglobin A(1C) (HbA(1C)) and also leads to significant weight reduction in patients with T2DM. Unfortunately, there are some limitations, e.g., severe hypersensitivity reaction to the drug and a glomerular filtration rate (GFR) < 30 mL/min/1.73 m(2). As with any drug, empagliflozin is also characterized by several side effects among which symptomatic hypotension, troublesome genital fungal infections, urinary tract infections and rare ketoacidosis are characteristic. |
format | Online Article Text |
id | pubmed-9775057 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97750572022-12-23 New Insights into the Use of Empagliflozin—A Comprehensive Review Forycka, Joanna Hajdys, Joanna Krzemińska, Julia Wilczopolski, Piotr Wronka, Magdalena Młynarska, Ewelina Rysz, Jacek Franczyk, Beata Biomedicines Review Empagliflozin is a relatively new drug that, as an inhibitor of the sodium–glucose cotransporter 2 (SGLT2), causes increased urinary glucose excretion and thus contributes to improved glycemic control, better glucose metabolism, reduced glucotoxicity and insulin resistance. Although its original use was to induce a hypoglycemic effect in patients with type 2 diabetes mellitus (T2DM), empagliflozin has also shown a number of other beneficial effects by demonstrating a nephroprotective effect, and it has proven to be a breakthrough in the treatment of heart failure (HF). Empagliflozin has been shown to reduce hospitalizations for HF and the number of deaths from cardiovascular causes. Empagliflozin treatment also reduces the incidence of renal events, including death from renal causes, as well as the risk of end-stage renal failure. Empagliflozin appears to be a fairly well-tolerated and safe drug. In patients with inadequate glycemic control, empagliflozin used in monotherapy or as an adjunct to therapy effectively lowers fasting blood glucose, postprandial blood glucose, average daily glucose levels, glycated hemoglobin A(1C) (HbA(1C)) and also leads to significant weight reduction in patients with T2DM. Unfortunately, there are some limitations, e.g., severe hypersensitivity reaction to the drug and a glomerular filtration rate (GFR) < 30 mL/min/1.73 m(2). As with any drug, empagliflozin is also characterized by several side effects among which symptomatic hypotension, troublesome genital fungal infections, urinary tract infections and rare ketoacidosis are characteristic. MDPI 2022-12-19 /pmc/articles/PMC9775057/ /pubmed/36552050 http://dx.doi.org/10.3390/biomedicines10123294 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Forycka, Joanna Hajdys, Joanna Krzemińska, Julia Wilczopolski, Piotr Wronka, Magdalena Młynarska, Ewelina Rysz, Jacek Franczyk, Beata New Insights into the Use of Empagliflozin—A Comprehensive Review |
title | New Insights into the Use of Empagliflozin—A Comprehensive Review |
title_full | New Insights into the Use of Empagliflozin—A Comprehensive Review |
title_fullStr | New Insights into the Use of Empagliflozin—A Comprehensive Review |
title_full_unstemmed | New Insights into the Use of Empagliflozin—A Comprehensive Review |
title_short | New Insights into the Use of Empagliflozin—A Comprehensive Review |
title_sort | new insights into the use of empagliflozin—a comprehensive review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775057/ https://www.ncbi.nlm.nih.gov/pubmed/36552050 http://dx.doi.org/10.3390/biomedicines10123294 |
work_keys_str_mv | AT foryckajoanna newinsightsintotheuseofempagliflozinacomprehensivereview AT hajdysjoanna newinsightsintotheuseofempagliflozinacomprehensivereview AT krzeminskajulia newinsightsintotheuseofempagliflozinacomprehensivereview AT wilczopolskipiotr newinsightsintotheuseofempagliflozinacomprehensivereview AT wronkamagdalena newinsightsintotheuseofempagliflozinacomprehensivereview AT młynarskaewelina newinsightsintotheuseofempagliflozinacomprehensivereview AT ryszjacek newinsightsintotheuseofempagliflozinacomprehensivereview AT franczykbeata newinsightsintotheuseofempagliflozinacomprehensivereview |